Sodium-Glucose Cotransporter Inhibitors
Inhibition of sodium-glucose transporters (SGLTs), particularly SGLT2, is a strategy for reducing plasma
glucose levels as a treatment for diabetes. Cayman offers a collection of high-quality SGLT1 and
SGLT2 inhibitors to help make your diabetes research possible.
Dapagliflozin
Item No. 11574
Empagliflozin
Item No. 17375
OH
OH
Selective SGLT2 inhibitor (Kis = 6 and 390 nM for
SGLT2 and SGLT1, respectively)
OH
O
Selective SGLT2 inhibitor (IC50 = 3.1 nM)
OH
OH
O
OH
O
fluoro-Dapagliflozin
OH
Cl
Item No. 15951
Phlorizin
Item No. 11576
HO
F
O
OH
Natural inhibitor of human SGLT1 and SGLT2
(Kis = 140 and 11 nM, respectively)
HO
O
O
HO
OH
O
Cl
O
OH
Analog of dapagliflozin that displays similar
selectivity for inhibiting SGLT2 over SGLT1
(Kis = 5.3 and 330 nM, respectively)
O
OH
Cl
Item No. 15952
Sotagliflozin
OH
OH
HO
galacto-Dapagliflozin
Item No. 19141
OH
Potent inhibitor of human SGLT2 (Kis = 2 and
25,000 nM for SGLT2 and SGLT1, respectively)
OH
O
OH
OH
O
OH
O
Cl
Orally available inhibitor of SGLT1 and SGLT2
(IC50s = 36 and 1.8 nM, respectively, for human
isoforms in vitro)
VIEW A COMPLETE LIST OF OUR DIABETES RESEARCH PRODUCTS AT
S
OH
O
OH
OH
O
Cl
WWW.CAYMANCHEM.COM